Trial
NCT02519842
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Chemotherapy-induced Nausea and Vomiting
Intervention
Fosaprepitant
Why stopped
Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-15